External broker reports(aggregated public sources), CMB International

CMB International

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>Biogen terminated partnership with InnoCare. On 15 Feb, Biogen terminated the collaboration with InnoCare on orelabrutinib for the treatment of multiple sclerosis (MS) and other autoimmune diseases.</li><li>The two parties started the collaboration in Jul 2021, and since then, InnoCare has received US$125mn upfront payment, and was eligible to receive up to US$812.5mn milestone payment and future sales royalties according to the original agreement.</li><li>However, due to the current termination, future payment will not happen, while InnoCare doesn’t need to return the upfront payment. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Biogen terminated partnership with InnoCare. On 15 Feb, Biogen terminated the collaboration with InnoCare on orelabrutinib for the treatment of multiple sclerosis (MS) and other autoimmune diseases.The two parties started the collaboration in Jul 2021, and since then, InnoCare has received US$125mn upfront payment, and was eligible to receive up to US$812.5mn milestone payment and future sales royalties according to the original agreement.However, due to the current termination, future payment will not happen, while InnoCare doesn’t need to return the upfront payment. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

InnoCare Pharma (9969 HK) – Breakup with Biogen on Orelabrutinib

InnoCare Pharma Ltd

InnoCare Pharma (9969 HK) – Breakup with Biogen on Orelabrutinib